https://valledellili.org/investigacion/ 2026-04-16T19:18:33+00:00 https://valledellili.org/investigacion/un-estudio-de-investigacion-para-evaluar-los-efectos-de-un-nuevo-medicamento-oral-llamado-cenerimod-en-adultos-con-lupus-eritematoso-sistemico-05648500/ 2026-02-07T00:40:14+00:00 https://valledellili.org/investigacion/estudio-de-nemtabrutinib-mk-1026-frente-a-un-comparador-a-eleccion-del-investigador-ibrutinib-o-acalabrutinib-en-leucemia-linfocitica-cronica-llc-linfoma-linfocitico-pequeno-sll-de-primera-li/ 2026-02-07T00:40:23+00:00 https://valledellili.org/investigacion/estudio-para-comparar-la-eficacia-y-la-seguridad-de-remibrutinib-frente-a-teriflunomida-en-participantes-con-esclerosis-multiple-05147220/ 2026-02-07T00:40:30+00:00 https://valledellili.org/investigacion/estudio-de-sacituzumab-tirumotecan-mk-2870-como-agente-unico-y-en-combinacion-con-pembrolizumab-mk-3475-frente-a-un-tratamiento-a-eleccion-del-medico-en-participantes-con-cancer-de-mama-localmente/ 2026-02-07T00:40:39+00:00 https://valledellili.org/investigacion/estudio-para-evaluar-el-cambio-en-el-estado-de-la-enfermedad-en-participantes-adultos-con-leucemia-mieloide-aguda-lma-que-recibieron-tabletas-orales-de-venetoclax-en-combinacion-con-azacitidina-inye/ 2026-02-07T00:40:49+00:00 https://valledellili.org/investigacion/estudio-para-evaluar-la-eficacia-y-seguridad-de-tulisokibart-mk-7240-en-participantes-con-colitis-ulcerosa-activa-de-moderada-a-grave-mk-7240-001-06052059/ 2026-02-07T00:40:56+00:00 https://valledellili.org/investigacion/eficacia-seguridad-y-farmacocinetica-de-vericiguat-en-pacientes-pediatricos-con-insuficiencia-cardiaca-por-disfuncion-sistolica-del-ventriculo-izquierdo-mk-1242-036-05714085/ 2026-02-07T00:41:05+00:00 https://valledellili.org/investigacion/subestudio-01a-seguridad-y-eficacia-de-tratamientos-combinados-con-opevesostat-mk-5684-u-opevesostat-solo-en-participantes-con-cancer-de-prostata-metastasico-resistente-a-la-castracion-cprcm-mk/ 2026-02-07T00:41:12+00:00 https://valledellili.org/investigacion/estudio-para-evaluar-la-eficacia-y-seguridad-de-tulisokibart-mk-7240-en-participantes-con-enfermedad-de-crohn-de-moderada-a-grave-mk-7240-008-06430801/ 2026-02-07T00:41:21+00:00 https://valledellili.org/investigacion/pembrolizumab-con-o-sin-mantenimiento-sacituzumab-tirumotecan-sac-tmt-mk-2870-en-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-escamoso-metastasico-mk-2870-023-06422143/ 2026-02-07T00:41:28+00:00 https://valledellili.org/investigacion/sacituzumab-tirumotecan-mk-2870-frente-a-terapia-combinada-de-pemetrexed-y-carboplatino-en-participantes-con-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-no-escamoso-avanzado-con-mutacion-del-fac/ 2026-02-07T00:41:35+00:00 https://valledellili.org/investigacion/estudio-para-evaluar-el-sacituzumab-tirumotecan-mk-2870-en-el-adenocarcinoma-gastroesofagico-avanzado-metastasico-mk-2870-015-06356311/ 2026-02-07T00:41:43+00:00 https://valledellili.org/investigacion/estudio-clinico-de-molnupiravir-para-la-prevencion-de-enfermedades-graves-por-coronavirus-2019-covid-19-en-personas-de-alto-riesgo-mk-4482-023-06667700/ 2026-02-07T00:41:50+00:00 https://valledellili.org/investigacion/estudio-de-belzutifan-mk-6482-mas-fulvestrant-para-el-cancer-de-mama-metastasico-er-her2-mk-6482-029-litespark-029-06428396/ 2026-02-07T00:41:57+00:00 https://valledellili.org/investigacion/estudio-de-fase-2-para-evaluar-morf-057-en-adultos-con-enfermedad-de-crohn-activa-de-moderada-a-grave-06226883/ 2026-02-07T00:42:05+00:00 https://valledellili.org/investigacion/estudio-clinico-de-tulisokibart-mk-7240-para-el-tratamiento-de-la-espondiloartritis-axial-radiografica-mk-7240-013-07133633/ 2026-02-07T00:42:11+00:00 https://valledellili.org/investigacion/estudio-clinico-de-tulisokibart-mk-7240-para-el-tratamiento-de-la-artritis-reumatoide-ar-mk-7240-014-07176390/ 2026-02-07T00:42:19+00:00 https://valledellili.org/investigacion/sacituzumab-tirumotecan/ 2026-02-07T00:42:26+00:00 https://valledellili.org/investigacion/estudio-de-fase-2-3-adaptativo-doble-ciego-controlado-con-placebo-para-evaluar-la-eficacia-y-la-seguridad-de-vx-147-en-sujetos-adultos-y-pediatricos-con-enfermedad-renal-proteinurica-053/ 2026-04-16T19:18:33+00:00